Aspergillosis in patients treated with monoclonal antibodies.
Invasive aspergillosis is a disease typically related with prolonged neutropenia or the use of corticosteroids. However, the increased use of new therapeutic modalities such as biologic agents that act by blocking specific immune pathways have put more patients at risk for invasive aspergillosis. Most cases of aspergillosis in patients taking monoclonal antibodies have been associated with the use of tumour necrosis factor (TNF)-alpha blockers. However, many more drugs have been implicated, including interleukin-2 inhibitors, and CD52 and CD20 blockers. In this manuscript we review the pathophysiology associated with an increased risk for aspergillosis in these patients, in addition to diagnostic and therapeutic considerations.
Nedel
Wagner L
WL
Serviço de Medicina Interna, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
Kontoyiannis
Dimitrios P
DP
Pasqualotto
Alessandro C
AC
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects; D001228:Aspergillosis / Q000209:etiology*; D006801:Humans; D007376:Interleukin-2 / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D000074323:Alemtuzumab